MedPath

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Conditions
Duchenne Muscular Dystrophy
Interventions
Registration Number
NCT06606340
Lead Sponsor
Sarepta Therapeutics, Inc.
Brief Summary

This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
Male
Target Recruitment
300
Inclusion Criteria
  • Is willing to provide informed assent or consent (if applicable) and has a parent(s) or legal guardian(s) or is a participant ≥18 years of age who is (are) willing to provide informed consent for the participant to participate in the study and comply with study data collection procedures.
  • Has an established clinical diagnosis of DMD, as documented prior to screening by a genetic report.
  • Receiving, or initiating treatment with, eteplirsen, golodirsen, or casimersen at the time of observational study enrollment. Note: Participants with a prescription for eteplirsen, golodirsen, or casimersen at enrollment must initiate the exon-skipping therapy within 6 months of the date of enrollment or will no longer be eligible for this study. Note: Enrollment of eteplirsen participants has been completed, no additional participants will be enrolled.

Key

Exclusion Criteria
  • Is currently participating in any DMD interventional study at the time of this study enrollment.

  • Has declined to provide consent for collection of their genetic data.

  • Has a medical condition or confounding circumstances that, in the opinion of the Investigator, might compromise:

    1. The participant's ability to comply with the protocol-required procedures
    2. The participant's wellbeing or safety, and/or
    3. The clinical interpretability of the data collected from the participant.

Other inclusion/exclusion criteria may apply.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
EteplirsenEteplirsen-
GolodirsenGolodirsen-
CasimersenCasimersen-
Primary Outcome Measures
NameTimeMethod
Loss of Ambulation (LOA)Up to 5 years
Time to Rise From the Floor (Supine to Stand)Up to 5 years
Time to Walk/Run 10 MetersUp to 5 years
Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item AUp to 5 years
Pulmonary Function, as Measured by Forced Vital Capacity (FVC) (% Predicted)Up to 5 years
Cardiac Function, Including Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram (ECHO)Up to 5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

Arkansas Children's Hospital Research Institute

🇺🇸

Little Rock, Arkansas, United States

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

University of California Davis Medical Center

🇺🇸

Sacramento, California, United States

Children's National Hospital

🇺🇸

Washington, District of Columbia, United States

University of Florida

🇺🇸

Gainesville, Florida, United States

University Of Iowa Hospitals And Clinics

🇺🇸

Iowa City, Iowa, United States

Kennedy Krieger Institute

🇺🇸

Baltimore, Maryland, United States

Washington University

🇺🇸

Saint Louis, Missouri, United States

Columbia University Medical Center - PIN

🇺🇸

New York, New York, United States

Duke Lenox Baker Children's Hospital

🇺🇸

Durham, North Carolina, United States

Atrium Health Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Penn State Health Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Children's Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

UPMC Children's Hospital of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

Cook Children's Hospital

🇺🇸

Fort Worth, Texas, United States

Texas Children's Hospital

🇺🇸

Houston, Texas, United States

UVA Children's Hospital

🇺🇸

Charlottesville, Virginia, United States

Seattle Children's Hospital

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath